Overview

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:
0

Participant gender:
All

Summary

The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, the investigators want to examine the influence of D2 receptor blockade on these disturbances. The investigators expect disturbances in the dopaminergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and investigators expect D2 receptor blockade to reverse some of the functional and cognitive impairments.

Phase:

N/A

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

University of Copenhagen

Collaborators:

Copenhagen Hospital Corporation
Glostrup University Hospital, Copenhagen
Institute of Psychiatry, London
Rigshospitalet, Denmark
UMC Utrecht

Treatments:

Amisulpride
Antipsychotic Agents
Aripiprazole
Sultopride

Criteria

Inclusion Criteria:

For patients: meeting diagnostic criteria for schizophrenia according to ICD 10 or DSM IV
antipsychotic naive The controls will be matched to the patients according to gender age
and parental socio-economic status.

-

Exclusion Criteria:

Patients: mental retardation, other chronic diseases, use of antidepressive medicine during
the last month,being pregnant, on going substance abuse

Controls: psychiatric diagnosis, psychiatric diagnosis in first-degree relatives,on going
drug abuse, mental retardation -